EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Join SI Premium – FREE
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.54), $0.02 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.06 million.
For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- L'Oreal SA (OR:FP) (LRLCY) PT Raised to EUR450 at Goldman Sachs
- 1st Source Corp (SRCE) Tops Q3 EPS by 20c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
